MBio Diagnostics has received a contract worth $629,595 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop and commercialise the point-of-care multiplex serology test to identify human anti-SARS-CoV-2 antibodies. MBio will now be able to finish the panel development and file for Emergency Use Authorisation (EUA).

The US Food and Drug Administration (FDA ) has granted Emergency Use Authorisation (EUA) to Biohit’s Sars-CoV-2 IgM/IgG antibody test kit. With this authorisation, the test kit can be used in CLIA-certified labs. The SARS-CoV-2 IgM/IgG Antibody Test Kit is said to have shown high IgM and IgG sensitivity and high specificity. The test also provides results within few minutes.

Brite-Strike Technologies has developed a UVC medical device that adds pathogen killing technology for N95 face masks. The micro device can be fitted on any N95 or a mask similar to the Under Armour Sportsmask and used along with hydrogen peroxide and a heat source to decontaminate it.

IgNova has filed a patent application for the use of passive immunisation to control SARS-CoV-2 infection. The company carried out research on technology for specific egg immunoglobulins (IgY). The IgY binds the spike protein of SARS-CoV-2 and neutralises the virus when it enters the body. The technology provides a safe, economical, and unlimited source of polyclonal antibodies to control the Covid-19 virus.